Incidence and predictors of understaging in patients with clinical T1 urothelial carcinoma undergoing radical cystectomy
- PMID: 24053444
- PMCID: PMC3874077
- DOI: 10.1111/bju.12245
Incidence and predictors of understaging in patients with clinical T1 urothelial carcinoma undergoing radical cystectomy
Abstract
Objective: To evaluate predictors of understaging in patients with presumed non-muscle-invasive bladder cancer (NMIBC) identified on transurethral resection of bladder tumour (TURBT) who underwent radical cystectomy (RC) with attention to the role of a restaging TURBT.
Patients and methods: We retrospectively evaluated 279 consecutive patients with clinically staged T1 (cT1) disease after TURBT who underwent RC at our institution from April 2000 to July 2011. In all, 60 of these cT1 patients had undergone a restaging TURBT before RC. The primary outcome measure was pathological staging of ≥T2 disease at the time of RC.
Results: In all, 134 (48.0%) patients were understaged. Of the 60 patients who remained cT1 after a restaging TURBT, 28 (46.7%) were understaged. Solitary tumour (odds ratio [OR] 0.43, 95% confidence interval [CI] 0.25-0.76, P = 0.004) and fewer prior TURBTs (OR 0.84, 95% CI 0.71-1.00, P = 0.05) were independent risk factors for understaging.
Conclusions: Despite the overall improvement in staging accuracy linked to restaging TURBTs, the risk of clinical understaging remains high in restaged patients found to have persistent T1 urothelial carcinoma who undergo RC. Solitary tumour and fewer prior TURBTs are independent risk factors for being understaged. Incorporating these predictors into preoperative risk stratification may allow for augmented identification of those patients with clinical NMIBC who stand to benefit most from RC.
Keywords: cystectomy; outcome and process assessment (health care); surgical pathology; urinary bladder; urinary bladder neoplasms.
© 2013 The Authors. BJU International © 2013 BJU International.
Figures
Similar articles
-
Role of immediate radical cystectomy in the treatment of patients with residual T1 bladder cancer on restaging transurethral resection.BJU Int. 2013 Jul;112(1):54-9. doi: 10.1111/j.1464-410X.2012.11391.x. Epub 2012 Nov 13. BJU Int. 2013. PMID: 23146082
-
Non-muscle invasive high grade urothelial carcinoma of the bladder. Which factors can influence understaging at the time of radical cystectomy?Arch Ital Urol Androl. 2016 Mar 31;88(1):13-6. doi: 10.4081/aiua.2016.1.13. Arch Ital Urol Androl. 2016. PMID: 27072170
-
The significance of lymphovascular invasion in transurethral resection of bladder tumour and cystectomy specimens on the survival of patients with urothelial bladder cancer.BJU Int. 2009 Feb;103(4):475-9. doi: 10.1111/j.1464-410X.2008.08011.x. Epub 2008 Oct 6. BJU Int. 2009. PMID: 18990174
-
Management of high-risk non-muscle invasive bladder cancer.Minerva Urol Nefrol. 2012 Dec;64(4):255-60. Minerva Urol Nefrol. 2012. PMID: 23288212 Review.
-
Upper urinary tract recurrence following radical cystectomy for bladder cancer: a meta-analysis on 13,185 patients.J Urol. 2012 Dec;188(6):2046-54. doi: 10.1016/j.juro.2012.08.017. Epub 2012 Oct 18. J Urol. 2012. PMID: 23083867 Review.
Cited by
-
Comparison of golden-angle radial sparse parallel (GRASP) and conventional cartesian sampling in 3D dynamic contrast-enhanced mri for bladder cancer: a preliminary study.Jpn J Radiol. 2024 Aug 1. doi: 10.1007/s11604-024-01637-w. Online ahead of print. Jpn J Radiol. 2024. PMID: 39088010
-
Preoperative Prediction of Muscle Invasiveness in Bladder Cancer: The Role of 3D Volumetric Radiomics Using Diffusion-Weighted MRI, the VI-RADS Score, or a Combination of Both.Ann Surg Oncol. 2024 Sep;31(9):5845-5850. doi: 10.1245/s10434-024-15760-5. Epub 2024 Jul 13. Ann Surg Oncol. 2024. PMID: 39003377
-
MRI evaluation of vesical imaging reporting and data system for bladder cancer after neoadjuvant chemotherapy.Cancer Imaging. 2024 Apr 8;24(1):49. doi: 10.1186/s40644-024-00696-6. Cancer Imaging. 2024. PMID: 38584289 Free PMC article.
-
Evaluation of Whole-Tumor Texture Analysis Based on MRI Diffusion Kurtosis and Biparametric VI-RADS Model for Staging and Grading Bladder Cancer.Bioengineering (Basel). 2023 Jun 21;10(7):745. doi: 10.3390/bioengineering10070745. Bioengineering (Basel). 2023. PMID: 37508772 Free PMC article.
-
Value of the application of computed tomography-based radiomics for preoperative prediction of unfavorable pathology in initial bladder cancer.Cancer Med. 2023 Aug;12(15):15868-15880. doi: 10.1002/cam4.6225. Epub 2023 Jul 11. Cancer Med. 2023. PMID: 37434436 Free PMC article.
References
-
- Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012 Jan;62(1):10–29. - PubMed
-
- Malmström PU, Busch C, Norlén BJ. Recurrence, progression and survival in bladder cancer. A retrospective analysis of 232 patients with greater than or equal to 5-year follow-up. Scand J Urol Nephrol. 1987;21(3):185–95. - PubMed
-
- Dwivedi US, Kumar A, Das SK, Trivedi S, Kumar M, Sunder S, et al. Relook TURBT in superficial bladder cancer: its importance and its correlation with the tumor ploidy. Urol Oncol. 2009 Sep;27(5):514–9. - PubMed
-
- Dutta SC, Smith JA, Shappell SB, Coffey CS, Chang SS, Cookson MS. Clinical under staging of high risk nonmuscle invasive urothelial carcinoma treated with radical cystectomy. J Urol. 2001 Aug;166(2):490–3. - PubMed
-
- Konety BR, Williams RD. Superficial transitional (Ta/T1/CIS) cell carcinoma of the bladder. BJU Int. 2004 Jul;94(1):18–21. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous
